CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. - Wikidata - awgldk - TriplyDB

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.

http://www.wikidata.org/entity/Q35871798

about

The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses A Perspective of Immunotherapy for Prostate Cancer Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy The progress of immunotherapy for glioblastoma Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy The GIST of targeted therapy for malignant melanoma Acquired and intrinsic resistance in cancer immunotherapy New modalities of cancer treatment for NSCLC: focus on immunotherapy Immune Checkpoint Blockade in Cancer Therapy Pathways and therapeutic targets in melanoma Immunotherapy advances for glioblastoma Immunotherapy in gastric cancer Targeting the innate immune system as immunotherapy for acute myeloid leukemia Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.Novel therapeutic options in Acute Myeloid Leukemia Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer Nivolumab in melanoma: latest evidence and clinical potential Mechanisms of action of therapeutic antibodies for cancer The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma Antibody Therapies in Cancer.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Melanoma: more answers, more questions Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression

P2860

Q24616434-70D9DD17-52A5-48F4-B67E-555EBC9BB158 Q26741277-1EB89F36-56A3-4654-8040-48492082FA96 Q26770391-28F47699-1FFC-40F8-834B-D2E72E61540E Q26775034-7D5D179E-8FD9-4A53-91BE-5A05928EE4B0 Q26782270-A2C5C1E4-B2A9-4AA9-A292-EED9E6A3BD51 Q26797282-C3D84A25-296A-42C3-9B32-ED3DDDE1FE0C Q26798404-46B17F3A-6503-49C5-A7D6-B414BC29D1DD Q26822793-D6409309-052A-4032-A2D2-44FA8ED26F77 Q26824310-DB8076CC-BADC-41C6-8EB8-73628B8AF6D1 Q26825053-0E5D7C29-AA97-4243-BDC5-227B900279CD Q26827092-C525FF04-1C6F-4FE0-9335-35DA33A497A7 Q26827701-A5810899-27BF-4D98-82FE-B3519447ACF8 Q26829161-E5BA1C5E-2AE9-42FC-BF43-358586367A87 Q26830509-E32FD131-5610-41E2-9066-A95B1471B08F Q26865736-79E655EA-85DE-4200-95B7-F9D7C09328EF Q26866513-35DDFA97-6AF9-4C45-AB88-EC2D854ED240 Q27010472-871A416D-1F37-4EFA-812E-8C94F70783F9 Q27015876-0B3D3454-D96B-453F-AE6D-17155D1330F7 Q27021570-938BE219-FAC1-4AD6-A613-2FB6180F9FA8 Q27691824-F5E25EFD-0E33-4570-802B-4CA60A4C5ED3 Q28069889-9019E753-D92C-43DE-9E06-2862BCD5B252 Q28076041-6EBC1A84-E64D-4C90-870E-511454574903 Q28258598-2BC80FFC-A6CA-4FC1-9BBB-D781A8DECCB1 Q28385366-F2BEED44-673F-4496-A3DA-37848B78D5AA Q28485085-A42B7A1C-A96A-435B-8DD8-C1BB7C6385C5 Q30746423-0D7039B4-4E0C-4BDD-BEC2-80F4AC7C721A Q30828178-BB94D919-306B-4E3F-8B23-012DB8D95A88 Q30890582-0E70AD68-E578-4CF4-8703-7550E2E3621C Q31104000-8A686B33-9997-4DA8-BF90-CCBCE77BCE71 Q33576170-57879A36-5E1C-45AF-AD2E-DA3FF85F860A Q33607108-CF40AD69-1299-4713-8C57-84226A18DA83 Q33620317-231AF5CB-B008-4590-8003-46203E3A588E Q33632113-8BC1C8A0-4B32-4DA0-A408-344BC02E5CB6 Q33643902-D3F0BD8E-BCE2-49A3-BE2E-77A73AFD5348 Q33667485-8F13DDE0-E7F7-475D-90D4-DA9AA4DE217E Q33718182-429E466A-0F9E-4326-AD78-BFD948251CCD Q33732329-51488BE2-8755-41B2-B16A-E03EECCDCDEB Q33777422-C382FAE3-4B12-4425-8768-FF33F0C6F68C Q33811204-EB05CD92-47A3-4F22-8549-4F4BB2957C1B Q33816848-F51642EE-A9B2-4861-80BB-B3DF210E5981

P2860

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.

http://www.wikidata.org/entity/Q35871798

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

CTLA-4 blockade with ipilimuma ...... ents with metastatic melanoma.

@ast

CTLA-4 blockade with ipilimuma ...... ents with metastatic melanoma.

@en

type

label

CTLA-4 blockade with ipilimuma ...... ents with metastatic melanoma.

@ast

CTLA-4 blockade with ipilimuma ...... ents with metastatic melanoma.

@en

prefLabel

CTLA-4 blockade with ipilimuma ...... ents with metastatic melanoma.

@ast

CTLA-4 blockade with ipilimuma ...... ents with metastatic melanoma.

@en

P1433

Q35871798-909209EA-5DC6-4BA9-9BA1-E623C63BA3F6

P1476

Q35871798-DE8A13BB-DE19-4CB5-A69D-16CA92F475C6

P2093

Q35871798-4188CD8B-6E90-410A-8C3C-F7EE1BCF9761

Q35871798-560FF4D1-612D-4E2D-A05C-72BF4B0C1194

Q35871798-64461ACD-8145-441B-A6C2-E19D862D25E0

Q35871798-783A5FF1-3BB9-467C-A64D-D6308D07A8A5

Q35871798-9BA4538D-3E02-4970-8DAE-F17D1708B5AA

Q35871798-A5A0E791-7C54-4887-B36F-D269EEC472B2

Q35871798-ABFA8384-FB53-40ED-8C92-9944A162B2CA

Q35871798-B9A271EE-0F86-49D3-B802-571D22615C1C

Q35871798-ECE151C1-456F-44B9-B12C-C9C0A69BC53A

P2860

Q35871798-084850E9-F77D-4C36-ABFF-D1185D82AE27

Q35871798-1AFE1559-70E0-4860-9D9A-D5E405DAFF7E

Q35871798-22F12471-D1AF-4B8C-B046-DFEB6676DEFF

Q35871798-2CAE2C57-DA8D-44CF-A77E-6A3B0872B36C

Q35871798-316BB15D-EB25-4D01-AFF0-BF8607234647

Q35871798-32D00E8C-9ABE-41F0-A909-0973970B87E0

Q35871798-34D8B7EE-248A-4641-B353-9BF489C97F8C

Q35871798-3743DF34-2765-4DDE-AD99-B196631F661A

Q35871798-3D47D101-9C50-4E76-8C87-CC46F7EC78B4

Q35871798-3F1D9D29-60E1-4222-981D-75E8AFFE61AA

P304

Q35871798-C31AED2D-E39E-452F-84DC-9B70FFBFE3BB

P31

Q35871798-A108FDFF-94B2-4A78-B27B-F977723E746B

P356

Q35871798-C3C83144-5C1F-4FF6-8EA7-6BE793E4432E

P407

Q35871798-6D278D81-23FC-413E-A3B4-0C64226145DB

P433

Q35871798-5F59A501-CF3F-4DE9-B59B-B0777FAB6C87

P478

Q35871798-FB787A4D-106B-4344-AC3D-0FC18036F770

P577

Q35871798-91EC2786-4FCE-4667-A7E3-D36BF14F6514

P698

Q35871798-0E785F8F-2179-4847-899A-3CA01EE15478

P921

Q35871798-36A0BCBB-9931-49B5-B6B5-B2A358C4175D

P932

Q35871798-16504EB9-3C3D-4275-BC41-D9F3989E001E

P356

1078-0432.CCR-11-1823

P1433

Clinical Cancer Research

P1476

CTLA-4 blockade with ipilimuma ...... ents with metastatic melanoma.

@en

P2093

Catherine L Levy

http://www.w3.org/2001/XMLSchema#string

Donald E White

http://www.w3.org/2001/XMLSchema#string

Giao Q Phan

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

Marybeth S Hughes

http://www.w3.org/2001/XMLSchema#string

Peter A Prieto

http://www.w3.org/2001/XMLSchema#string

Richard M Sherry

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

Udai S Kammula

http://www.w3.org/2001/XMLSchema#string

P2860

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

CTLA-4 ligation blocks CD28-dependent T cell activation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

P304

2039-2047

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-1823

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22271879

http://www.w3.org/2001/XMLSchema#string

P921

P932

3319861

http://www.w3.org/2001/XMLSchema#string